Keryx Biopharmaceuticals Inc (KERX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

ONE MARINA PARK DR. BOSTON, MA 02210

Acquires, develops and commercializes novel pharmaceutical products for the treatment of life-threatening diseases. As of Dec. 31, 2005, the company's lead product candidates were Sulonex for the treatment of diabetic nephropathy and KRX-0401 for the treatment of multiple forms of cancer.

Data based on most recent fiscal year report
Market Cap478.072 Million Shares Outstanding119.22 Million Avg Volume2.345 Million
1-Yr BETA vs S&P TR Current Ratio3.12 Quick Ratio2.49
View SEC Filings from KERX instead.
Q4 2018 All Institutions Hedge Funds 1
To trade KERX now:
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 1 0 (0.0%)
Aggregate 13F shares on 12/31/2018: 1 0
Aggregate 13F shares on 09/30/2018: 70.595 Million 37.967 Million
Percent change: -100.00% -100.00%
Funds creating new positions:
Funds Adding to an existing position:
Funds closing out their position: 116 21
Funds reducing their position:
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

 

Keryx Biopharmaceuticals Inc Chart by YCharts

Yahoo! Finance

finviz

Check out our reporting and analysis

Funds Holding KERX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HEFFERNAN MICHAEL THOMAS

  • Director
 227,362 2019-03-15 2

BUTLER JOHN P. CEO AND PRESIDENT

731,182 2019-02-28 0

GILMAN STEVEN C

0 2019-02-28 4

ENYEDY MARK J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 483,768 2019-02-22 2

ROGERS MICHAEL W CHIEF FINANCIAL OFFICER

  • Officer
 0 2019-02-15 2

KAYE JACK

  • Director
 72,707 2019-02-12 0

TARNOK MICHAEL P.

  • Director
 188,929 2019-02-12 0

OLIVIERO JAMES F III CEO, PRESIDENT AND DIRECTOR

  • Officer
  • Director
 2,135,000 2019-01-24 0

BENTSUR RON CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 38,113 2019-01-01 0

CAMERON KEVIN J

  • Director
 No longer subject to file 2018-12-12 5

REGAN DANIEL PAUL

  • Director
 No longer subject to file 2018-12-12 2

NEYLAN JOHN F. CHIEF MEDICAL OFFICER

  • Officer
 No longer subject to file 2018-12-12 8

HOLMES SCOTT A CHIEF FINANCIAL OFFICER

  • Officer
 No longer subject to file 2018-12-12 7

MORRISON JODIE POPE INTERIM CEO

  • Officer
  • Director
 No longer subject to file 2018-12-12 3

CARBERRY CHRISTINE A. CHIEF OPERATING OFFICER

  • Officer
 No longer subject to file 2018-12-11 4

BAUPOST GROUP LLC/MA

BAUPOST GROUP GP, L.L.C.

KLARMAN SETH A

  • Director
  • 10% Owner
 No longer subject to file 2018-12-11 2

ROSE ERIC A MD

993,094 2018-11-22 0

WEISS MICHAEL S

  • Director
 24,663 2018-08-07 0

HOENLEIN MALCOLM

  • Director
 78,033 2018-06-06 0

FECZKO JOSEPH M

  • Director
 90,517 2018-05-21 0

MADISON GREG PRESIDENT AND CEO

  • Officer
  • Director
 566,586 2018-03-20 0

ADAMS BRIAN GENERAL COUNSEL AND SECRETARY

  • Officer
 126,069 2018-02-15 0

BAUPOST GROUP LLC/MA

SAK CORP

KLARMAN SETH A

  • 10% Owner
 22,268,399 2016-03-15 0

FOWLER WYCHE JR

  • Director
 No longer subject to file 2015-06-17 0

HENDERSON CRAIG PRESIDENT

  • Officer
  • Director
 0 2007-12-30 0

LEVINE BETH F SVP, GC, CCO AND SECRETARY

  • Officer
 0 2007-12-30 0

STIER MARK CHIEF ACCOUNTING OFFICER

  • Officer
 0 2007-12-30 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments